Trial Profile
Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2012
Price :
$35
*
At a glance
- Drugs Gandotinib (Primary)
- Indications Myeloproliferative disorders; Solid tumours
- Focus Pharmacokinetics
- 02 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 23 Apr 2012 New trial record